Borrelia burgdorferi, the etiologic agent of Lyme borreliosis, is found in parts of North America, Europe, Asia, and other temperate regions of the world. Clinical illnesses produced by infection with B. burgdorferi are diverse and can include arthritic, neurologic, dermatologic, and cardiac manifestations. In North America, arthritis is a predominant symptom, while in Europe neurologic and cutaneous symptoms are more common (27) . Evidence suggests that particular disease manifestations are related to the genospecies of the infecting spirochete and that geographic differences in genospecies distribution may account for regional variations in clinical disease patterns (1, 13, 27, 30, 32) .
Molecular and serological studies have delineated four genospecies (genogroups) within the species of B. burgdorferi sensu lato (8) . Genospecies 1, B. burgdorferi sensu stricto, is found in North America and Europe. Genospecies 2, Borrelia garinii, and genospecies 3, Borrelia afzelii, are found in Europe and Asia (2) . Genospecies 4, Borrelia japonica, the most recently recognized group and one which has yet to be shown to be a human pathogen, is found in Japan (17) . Additional isolates have been described which do not appear to belong to any of the genospecies described above, and it is likely that other genospecies will be delineated.
In North America, serologic assays based on a low-passage B. burgdorferi sensu stricto strain antigen are currently recommended (9) . In Europe, the presence of three major genospecies has raised concern that the potential diversity of antibody responses seen in European sera may not be recognized by serodiagnostic tests with antigen prepared from heterologous isolates, especially North American strain B31 (genospecies 1).
Since Lyme borreliosis can generally be treated once diagnosed and laboratory support for the diagnosis of B. burgdorferi infection is largely dependent on serological assays, the definition and use of optimal antigen preparations are critical to the performance and clinical utility of B. burgdorferi serological assays. Magnarelli et al. (21) concluded that the use of antigens from local strains was not critical to their enzyme immunoassay's (EIA's) overall sensitivity or specificity, although the use of antigens from particular strains did result in overall higher levels of reactivity. In a related study, Karlsson (14, 16) reported that although one of four patients showed increased reactivity to the autologous infecting strain, whole-cell extracts from different isolates seemed to be of comparable diagnostic value in their EIA. A recent report from Sweden, however, demonstrated the potential significance of strain selection in assay design. In this study, EIAs prepared with a local B. garinii strain detected a higher number of seropositive individuals in an area in which borreliosis is endemic compared with that detected by an EIA prepared with B31 antigen. On the other hand, when sera from North American Lyme borreliosis patients were tested, higher numbers of seropositive sera were detected with a B31 antigen-based EIA (7) .
In the present study, we investigated this issue by testing a panel of European and North American Lyme borreliosis sera representing a range of clinical states and geographic regions on Western blots (immunoblots) prepared with eight B. burgdorferi sensu lato isolates representing the three major genospecies to determine the relative reactivity of the specimens to the various strains. Our primary objective was to determine which strain or strains were the best candidates for use in preparing Western blots for general use in Europe.
(Portions of this work were presented as abstract P117T at the VI International Conference on Lyme Borreliosis, 19 to 22 June 1994, Bologna, Italy.) MATERIALS AND METHODS Study samples. Physicians in each of the study countries were asked to submit specimens they believed to be consistent with Lyme borreliosis. Physicians were also asked to provide information about the clinical symptoms of the patients. A total of 69 European and 8 North American specimens were examined in this study.
Borrelia culture and antigen preparation. Eight Borrelia strains representing the three major genospecies were examined in this study. The specific isolates studied were B. burgdorferi sensu stricto (genospecies 1) B31, 297, and CB from the United States and the IRS isolate from Switzerland; B. garinii (genospecies 2) 20047 (France) and PBi (Germany); and B. afzelii (genospecies 3) VS461 (Switzerland) and B023 (Germany). Borrelia was grown in BSK II medium at 32ЊC. Bacteria were harvested by centrifugation at 4ЊC and washed three times with phosphate-buffered saline (PBS [pH 7.2]). The final pellet was resuspended in PBS and frozen in aliquots at Ϫ70ЊC. Protein determinations were performed with the Pierce bicinchoninic acid (BCA) protein assay. All eight strains were assayed together on a single run for maximum standardization of protein loading on the gels.
SDS-PAGE and Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by standard procedures (18 (29) . Transfer uniformity and efficiency were verified by Ponceau S staining of each blot. Blots were blocked with nonfat dry milk in 0.05% Tween 20 in PBS (PBST) and cut into 3-mm strips. Antigen strips were incubated with 1:100 dilutions of patient sera for 1 h, washed with PBST three times, incubated with goat antihuman immunoglobulin G (IgG)-alkaline phosphatase (MRL Diagnostics) for 30 min, and washed again three times with PBST, and the antibody reactivity was visualized by incubation with 5-bromo-4-chloro-3-indolylphosphate toluidiniumnitroblue tetrazolium substrate (MRL Diagnostics). Reactive bands observed on each strip were scored independently by two readers.
Monoclonal antibodies. A panel of nine monoclonal antibodies, including antibodies specific for p22 (referred to as p21 throughout text), OspC (p23), OspD (p29), OspA (p31), OspB (p34), BmpA (p39), Fla (p41), GroEL (p62), and p93, was kindly provided by Marty Schriefer of the Centers for Disease Control. These nine antibodies were combined into a cocktail and reacted with Western blot strips. Monoclonal antibodies specific for p18 and p30 proteins were kindly provided by Karim E. Hechemy from the New York State Department of Health. Refer to Table 1 for details about the monoclonal antibodies used.
RESULTS

Reactivity of
Borrelia strains with the monoclonal antibody panel. The reactivity of the eight Borrelia strains with the monoclonal antibody cocktail is shown in Fig. 1 . Included in Fig. 1 is strain PG1, which is a strain we recently isolated from a Lyme borreliosis patient from the United States. This strain reacts similarly to strain CB and will not be discussed further. In addition, the strains were reacted with monoclonal antibodies to p18 (NYSP18 a H1) and p30 (NYSP30H1) (results not shown in Fig. 1 ). The reactivity of the various monoclonal antibodies to the strains is summarized in Table 1 . All strains showed similar reactivity to the p18, p21, p30, p41, GroEL (p62), and p93 antibodies; however, VS461 and B023 showed weak reactivity to p21. VS461 did not show any reactivity to the p93 monoclonal antibody; however, the presence of p93 was clearly demonstrated when VS461 (as well as all of the other seven strains) was reacted with sera from a German Lyme borreliosis patient (data not shown). The OspC (p23) monoclonal antibody reacted to all strains except B023. Reactivity to the OspB (p34) monoclonal antibody was not detected in strains 20047 or IRS, while reactivity to the OspA (p31) monoclonal antibody was not detected in PBi, VS461, or B023. No reactivity to the OspD monoclonal antibody was detected in any of the strains examined.
Serologic reactivity of B. burgdorferi strains with Lyme borreliosis sera. Specimens were reacted with Western blot strips prepared from each of the eight Borrelia strains, and IgG reactivity to protein bands corresponding to p15, p18, p21, p23 (OspC), p28, p31 (OspA), p34 (OspB), p39, p41, p66, p75, and p93 was scored. As a result of the small volume of many of the specimens available to us, only IgG reactivity was evaluated in the present study. The strains exhibiting the two highest band scores for each specimen were designated as "preferentially reactive" for that specimen. Table 2 summarizes the number of specimens within each geographic group which were preferentially reactive for each strain. Most sera demonstrated preferential reactivity to multiple strains.
The European sera were generally more reactive to B. garinii and B. afzelii strains than to B. burgdorferi sensu stricto strains. An example of the different reactivities of sera to different Borrelia strains is shown in Fig. 1B . The U.S. specimen intensely reacted to the p18 and p23 (OspC) bands of genospecies 1 strain CB (a U.S. isolate) but did not react to either of these bands on the 20047 strips. In a similar manner, the p93 181.1 20 P P P P P P N P GroEL (p62) 149 19 P P P P P P P P Fla (p41) H9724 3 P P P P P P P P BmpA (p39) H1141 26
NYSP18 a H1 13a P P P P P P P P a N, negative; P, positive; SP, strong positive. German sera reacted intensely to the p18 and p23 (OspC) bands of the 20047 strain but only weakly to the p18 and p23 (OspC) bands of the CB strain. Both serum samples reacted strongly to the p21 band of each strain. In the case of these particular sera, the absence of the p18 or p23 bands on either strip would not affect the positive interpretation, since the sera are very reactive to multiple bands. In other cases, however, the lack of reactivity to these bands, especially OspC, could be very significant for interpretation. To date, no consensus has been reached on Western blot criteria for interpretation of European specimens as "positive" or "negative." We therefore, interpreted the reactivity observed for each of the Borrelia strains by using a criterion established in our clinical laboratory for North American specimens tested with B. burgdorferi sensu stricto B31. By this criterion, a positive result required any four of the following bands: p18, p21, p23 (OspC), p27, p31 (OspA), p34 (OspB), p39, p41, p66, p75, or p93. The results of this analysis were similar to those found by the analysis of preferential reactivity ( Table 3 ). The strains which would result in the assignment of the most positives (i.e., the strains with the highest sensitivity) were B. garinii 20047 and PBi, followed by B. afzelii VS461, and B. burgdorferi sensu stricto CB and IRS.
Five of 69 (7.2%) European Lyme borreliosis specimens would have changed between a positive or negative interpretation, depending on the strain used to prepare the Western blot. One of the eight North American specimens tested would also have changed interpretation. When the data from both groups are combined, the interpretation of 6 of 77 (7.8%) would change, depending on the strain used for analysis. Western blot reactivity of clinically defined sera. When specimens were grouped by reported clinical status and their preferential reactivity to the various strains was evaluated, the nerve and/or palsy group was found to be most reactive with B. garinii 20047 and PBi, followed by B. afzelii VS461 and B. burgdorferi sensu stricto CB (Table 3 ). The asymptomatic group demonstrated similar reactivity to strains 20047 and VS461. The arthritis group was preferentially reactive to strains 20047 and VS461, while the erythema migrans group was preferentially reactive to strain IRS.
In addition to the examination of preferential reactivity, the average number of bands detected for each strain and genospecies for each clinical group was determined ( Table 4) (Table 5) .
DISCUSSION
The recognition of multiple genospecies of B. burgdorferi differing in their molecular and antigenic properties has led to concern about the detection of B. burgdorferi infections by assays with heterologous antigens (4) . In the present study, we evaluated the relative effectiveness of various B. burgdorferi strains representing the three major genospecies for the detection of Lyme borreliosis in European specimens.
Studies of Lyme borreliosis Western blots have been hampered by problems of band identification and nomenclature. Resolution of the uncertainty of particular band location and equivalence must be achieved in order for new criteria to be evaluated by investigators at different geographic locations with different antigens and gel systems. The use of calibrating panels of monoclonal antibodies such as that provided by the Centers for Disease Control will help alleviate this problem. In the present study, in addition to the monoclonal antibodies included in the Centers for Disease Control panel, we were able to use monoclonal antibodies provided by K. Hechemy to identify p18 and p30 proteins. A manuscript characterizing the NYSP18 a H1 (for p18) and NYSP30H1 (for p30) monoclonal antibodies is in preparation (13a). The p18 protein has been a particular problem, since some investigators have referred to it as p21 and some have referred to it as p18. Figure 1A clearly shows three distinct bands corresponding to the p18, p21, and p23 proteins. Each of these proteins has been identified by a specific monoclonal antibody. The location of the p30 band, which has also often been difficult to determine, can be identified with the NYSP30H1 antibody. Assignment of a consistent nomenclature to the bands is critical if meaningful interpretive criteria for these bands, such as the Centers for Disease Control-Association of State and Territorial Public Health Laboratory Directors recommendations (9) , are to be developed, refined, and accurately applied.
Since there are no established criteria for interpretation of European Lyme borreliosis Western blots, the number of bands detected with each strain was used to determine the strain or strains which demonstrated preferential reactivity. We found that European sera were generally more reactive with B. garinii 20047 and B. afzelii VS461, while North American sera were more reactive with B. burgdorferi sensu stricto 297, CB, and IRS. The results with the Belgian and Spanish panels, however, in which B. burgdorferi sensu stricto CB and IRS, respectively, scored as well as the B. garinii and B. afzelii strains, indicate that the preferential reactivity to genospecies 2 and 3 is not absolute and that regional variations in the reactivity to the genospecies strains may occur. Since arthritic symptoms have commonly been associated with B. burgdorferi sensu stricto strains and nerve and/or palsy symptoms have been associated with the B. garinii genospecies, the results observed with the Belgian panel may partly be explained by the makeup of the Belgian panel, in which 36% (5 of 14) of the specimens were in the arthritis group and 9 of the remaining 14 specimens were in the palsy group. In the case of the Spanish panel, only 2 of 12 specimens were from patients with arthritic symptoms. Although the Belgian sera did react to strains representing all three genospecies, the striking preferential reactivity to the B. garinii and B. afzelii strains and one specific strain of B. burgdorferi sensu stricto underscores the need to carefully validate the use of B. burgdorferi sensu stricto strains for testing European sera. While a genospecies 1-based assay may be as effective as a B. garinii-or a B. afzelii-based assay for some regions, in others a B. garinii-or B. afzelii-based assay may be more effective.
While the overall level of reactivity is of interest, once the threshold value for an enzyme-linked immunosorbent assay (ELISA)-positive result or a certain number of designated bands on a Western blot-positive result is reached, additional reactivity (evaluated either by optical density or bands) is irrelevant for the interpretation and does not necessarily add to the clinical utility of the assay. Analysis of our results by looking at the number of positive or negative results obtained with each strain is complicated by the lack of established criteria for (15, 33) , more study is needed to determine if generic criteria could be used for blots prepared with antigens from different genospecies or even different strains within a genospecies. Our results showing different levels of reactivity with different strains suggest that development, optimization, and validation of Western blot criteria must be done for each specific strain. Cognizant of its limitations, we applied the Western blot criteria established for North American strains in use in our laboratory at the time of this study to assign a positive or negative interpretation to our Western blot results. The results of this analysis were similar to the preferential reactivity results, with B. garinii strains showing the most positive results, followed by the B. afzelii and B. burgdorferi sensu stricto strains. Our finding that 7.2% of the specimens would have been interpreted differently depending on the strain used is in general agreement with that seen with the ELISA studies showing small differences in performance (7, 14, 21) . Although the 7.2% number is small, it does show that the strain choice is significant (a positive to negative result) in some cases. The degree of impact of strain choice on a particular area will depend on the prevalence of particular strains in the test area. The results of Bunikis et al. (7), for whom an enzyme immunoassay prepared with the local B. garinii strain detected more seropositive individuals than an assay with B. burgdorferi sensu stricto B31, support this result. While strain differences are probably not critical for most ELISAs or other screening assays, strain differences are likely to be more important for the Lyme borreliosis Western blot assays in which reactivity to discrete proteins is scored and the specific profile of reactivity (the number and the identity of the specific bands) is critical to the interpretation of results.
In practical terms, any Western blot used in Europe will be challenged by a variety of clinical specimens from a wide geographic region. Analysis of the overall performance of the strains was assessed by evaluating each strain's performance with the complete panel of European specimens. When strains were evaluated either by the criterion of being preferentially reactive to the European specimens or by determination of the strains detecting the highest number of bands, B. garinii 20047 and B. afzelii VS461 demonstrated the best overall performances (Tables 2 and 3 ). On the basis of these two analyses, either VS461 or 20047 would be a candidate for use in a generic European Western blot. A difference between the performance of the two strains, however, was observed when interpretative criteria were applied to the blot results. In this case, strain 20047 detected five more positive specimens than strain VS461. It should be recognized that the criteria applied were developed for North American Lyme borreliosis sera tested with B. burgdorferi sensu stricto B31, and it is possible that alternative criteria would lead to different results.
Several studies have reported an association between clinical symptoms and preferential reactivity to particular genospecies. Our results showing the nerve and/or palsy groups were most reactive with the two B. garinii strains 20047 and PBi support the preferential reactivity of patients with nerve and/or palsy clinical histories with B. garinii strains reported by others (1, 6, a Note that the following bands were scored: p15, p18, p21, p23 (OspC), p28, p31/p32 (OspA), p34 (OspB), p39, p41, p66, p75, and p93. a Note that the positive criterion used was the presence of any four of the following bands: p18, p21, p23 (OspC), p28, p31/p32 (OspA), p34 (OspB), p39, p41, p66, p75, or p93. 13, 30, 32) . The strong reactivity of patients reported to have arthritic symptoms to B. garinii 20047, B. afzelii VS461, and B. burgdorferi CB is interesting in light of the association of arthritis and genospecies 1 strains (27) . Although arthritis is regarded as a more common clinical symptom in North America, the arthritis group represented the second largest clinical group among the European specimens in the present study. Assous et al. (1) recently reported a preferential reactivity of specimens from patients with arthritis to B. burgdorferi sensu stricto strains compared with B. garinii and B. afzelii strains. Our results for the arthritis group showed similar reactivity to B. garinii and B. afzelii strains and to two of the four B. burgdorferi sensu stricto strains. The reactivity of the European arthritis group specimens to B. garinii and B. afzelii strains in addition to the B. burgdorferi sensu stricto strains might be explained by either the unreported presence of other clinical symptoms in addition to arthritis, by current or past infection with multiple Borrelia strains, or by cross-reactivity between the 20047, VS461, and CB strains as a result of the strong immune response of these specimens (12, 31, 32) . The association of cutaneous manifestations of Lyme borreliosis with B. afzelii strains reported by others (1, 30, 32) was supported in this study, in which B. afzelii VS461 detected the highest average number of bands for this patient group.
B. burgdorferi genospecies are distributed throughout Europe, and the prevalence of particular genospecies varies in different regions. In some areas, all three genospecies may be present, while in other areas one or two species may predominate (2, 22, 24) . We did find that some Borrelia strains were more reactive in certain regional panels: for example, B. garinii for the Belgian panel and a European genospecies 1 strain (IRS) for the Spanish panel. This may reflect a true preferential reactivity to strains in these areas, or it may reflect the particular clinical makeup of the panels submitted by investigators from each region.
Accurate serodiagnosis is critical for detection of B. burgdorferi infection and to support clinical diagnosis. The study we have presented has shown that the choice of particular B. burgdorferi strains for preparation of Lyme borreliosis Western blots does affect the level of reactivity detected with specific European sera. Variable levels of reactivity between different strains may have consequences for the application of generic interpretative criteria for Lyme borreliosis Western blot seropositivity, and therefore criteria must be carefully validated for performance with each assay antigen. In addition, assays must be validated with specimens which represent the intended geographic test target area, since the prevalence of Borrelia strains is not uniform throughout Europe. In our study, we found that while the performances of B. garinii 20047 and B. afzelii VS461 were approximately equivalent in several analyses with the panel of European sera tested, B. garinii 20047 was more sensitive in discriminating positive specimens. In no cases would the use of B. burgdorferi sensu stricto strains offer performance advantages over the use of B. garinii or B. afzelii strains for testing the European sera, and in several cases, significantly lower levels of reactivity were observed. The next phase of this work will address the optimization of interpretative criteria for a B. garinii Western blot for the serodiagnosis of Lyme borreliosis in Europe.
